NCT03593707已完成1 期
A PHASE 1, RANDOMIZED, OPEN-LABEL, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE EFFECT OF PF-06865571 ON THE PHARMACOKINETICS OF METFORMIN IN HEALTHY ADULT SUBJECTS
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Maximum Observed Plasma Concentration (Cmax) of Metformin (in absence of PF-06865571)
研究概览
简要总结
This study is designed to assess the effect of PF-06865571 administration on the pharmacokinetics of metformin in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years.
- •Body mass index of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
- •Evidence of a personally signed and dated informed consent document.
- •Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •Any condition possibly affecting drug absorption (eg, gastrectomy).
- •A positive urine drug test.
- •History of regular alcohol consumption exceeding 14 drinks/week for female subjects or 21 drinks/week for male subjects.
- •Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product (whichever is longer).
- •Screening supine BP >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of supine rest.
- •Screening supine 12-lead ECG demonstrating a corrected QT (QTc) interval >450 msec or a QRS interval >120 msec.
- •Subjects with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level >=1.25× upper limit of normal (ULN);
- •Total bilirubin level >=1.5× ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is <=ULN.
- •Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and through the follow up contact, or have female partners that are pregnant.
- •Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
- •Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- •History of sensitivity to heparin or heparin-induced thrombocytopenia only if heparin is used to flush any intravenous catheters in the study.
- •History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing at the screening visit for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb). While not part of the tests assessed in this study, subjects with a positive hepatitis B surface antibody (HepBsAb) result due to vaccination are deemed eligible.
- •Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of this protocol.
- •Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
- •Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •Subjects who have participated in prior studies with PF-06865571.
研究组 & 干预措施
Metformin Alone
Experimental
Metformin alone
干预措施: Metformin (Drug)
Metformin + PF-06865571
Experimental
Co-administer metformin and PF-06865571
干预措施: Metformin (Drug)
Metformin + PF-06865571
Experimental
Co-administer metformin and PF-06865571
干预措施: PF-06865571 (Drug)
结局指标
主要结局
Maximum Observed Plasma Concentration (Cmax) of Metformin (in absence of PF-06865571)
时间窗: 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 48 hours post-dose
Metformin Cmax in absence of PF-06865571
Metformin Cmax (in presence of PF-06865571)
时间窗: 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 48 hours post-dose
Metformin Cmax in presence of PF-06865571
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Metformin (in absence of PF-06865571)
时间窗: 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 48 hours post-dose
Metformin AUCinf in absence of PF-06865571
Metformin AUCinf (in presence of PF-06865571)
时间窗: 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 48 hours post-dose
Metformin AUCinf in presence of PF-06865571
次要结局
- Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)(Baseline up to 35 days after last dose of study medication)
- Number of Participants With Laboratory Abnormalities(Baseline up to 35 days after last dose of study medication)
- Number of Participants With Clinically Significant Change From Baseline in Vital Signs(0 and 48 hours (h) post-dose)
- Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings(0 and 48 h post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study for MR Formulation of PF-06650833 in Healthy Adult Japanese SubjectsHealthyNCT02936154Pfizer10
已完成
1 期
A Study of PF-07258669 In Healthy Adult ParticipantsHealthy ParticipantsNCT05113940Pfizer120
终止
1 期
Safety and Tolerability of PF-06818883 in Healthy SubjectsHealthyNCT03020784Pfizer30
已完成
2 期
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.Pulmonary Disease, Chronic ObstructiveNCT00783406Pfizer20
已完成
1 期
Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult SubjectsHealthyNCT03599063Pfizer63